NICE finalises widened access to Alzheimer's drugs
This article was originally published in Scrip
Executive Summary
NICE, the health technology institute for England and Wales, has published final guidance widening access to Pfizer/Eisai's Aricept (donepezil), Shire's Reminyl (galantamine), Novartis's Exelon (rivastigmine) and Lunbeck's Ebixa (memantine) for Alzheimer's disease. The guidance formally replaces older, contentious recommendations and follows much legal wrangling.